乳腺小管癌6例临床分析

目的探讨乳腺小管癌的临床特征和合理的诊治方法。方法回顾分析我院收治的6例小管癌的诊治经过,并结合文献进行讨论。结果小管癌恶性程度低,预后良好,普及钼靶和高频超声检查有助于提高早期诊断率,改良根治术可作为基层医院主要治疗手段。结论由于小管癌恶性程度低,今后应尽量选择低创伤性的治疗手段,在保证治疗效果的前提下减少对患者的打击,避免过度治疗。     

雌、孕激素受体和Her-2阴性乳腺癌的临床病理特征

Objective To study the clinicopathologic characteristics of triple-negative breast cancer (TNBC) and its value in the prediction of prognosis. Method In this study,500 cases of female breast cancers were examined immunohistochcmically for the TNBC. The clinicopathologic characteristics of the 243 TNBC cases were inspected. Results TNBC accounted for 17.6% (88/500) of the 500 breast cancers. The histological types of the TNBC included mainly infihrative ductal carcinoma, metaplastic carcinoma and medullar carcinoma. Among those, histological grade Ⅲ accounted for 72.7% (64/88) of all the TNBC and was more common than that in hormone receptor positive breast cancers (HR+ group ) and Her-2 overexpression breast cancers (Her-2 group)(P=0.000). The positive rates of CK5/6 and EGFR in the TNBC were 30.7% (27/88) and 34.1% (30/88), respectively. The positive rates of ERCC1 and KIT in the TNBC were 28.4% (25/88) and 34.1% (30/88), respectively, Both of which were higher than those in the HR + group and Her-2 group, respectively (P=0.032 and P=0.026). 3-year survival rate of the TNBC was 71.5% and it was lower than that of HR group (P=0.021) and not significantly different from that of Her-2 group (P=0.474). Conclusions TNBC is the breast cancer with high aggressive pathologic futures and poor prognosis. EGFR and ERCC1 expression were positive in a portion of TNBC cases.     

乳腺小管癌7例临床分析

目的 探讨乳腺小管癌的临床特征和合理的诊治方法.方法 回顾分析我科收治的7例乳腺小管癌病例的诊治经过,并结合文献进行讨论.结果 乳腺小管癌恶性程度低,预后良好,普及钼靶和高频超声检查有助于提高早期诊断率,改良根治术可作为基层医院主要治疗手段.结论 由于小管癌恶性程度低,今后应尽量选择低创伤性的治疗手段,在保证治疗效果的前提下减少对患者的打击,避免过度治疗.     

负压引流在乳腺癌根治术后的应用

皮下积液是乳腺癌根治术后的常见并发症之一，积液是细菌的良好培养基。可导致切口感染、皮瓣坏死等不良后果。为减少皮下积液，促使皮瓣与胸壁粘连．常用方法是术后行皮瓣下引流同时行胸壁加压包扎。我院从2002年5月至2003年7月试行乳腺癌根治术后单纯皮瓣下负压球引流，取得满意效果，报告如下。     

TAC方案用于乳腺癌新辅助化疗的疗效观察

目的 探讨TAC方案在局部晚期乳腺癌患者术前新辅助化疗中的疗效.方法 回顾性分析82例局部晚期乳腺癌患者临床资料,全部患者均接受TAC方案新辅助化疗,观察化疗后患者临床总有效率、近期毒副反应和手术情况.结果 82例乳腺癌患者9例病理完全缓解(11.0％),21例达到CR(25.6％),47例达到PR(57.3％),14例达到SD(17.1％),临床总有效率82.9％.毒副反应主要以骨髓抑制为主,白细胞减少发生率达81.7％.其他不良反应还包括消化道症状和肝功能损害、脱发等.所有患者经对症处理后均可耐受.结论 TAC方案新辅助化疗用于局部晚期乳腺癌患者可提高其治愈率,增加保乳机会.     

雌、孕激素受体和Her-2阴性乳腺癌的临床病理特征

目的 评价雌、孕激素受体和Her-2表达均阴性乳腺癌(triple-negative breast cancer,TNBC)的临床病理特征及其对预后的影响.方法 500例乳腺癌采用免疫组化筛选TNBC,观察TNBC的临床病理特征,并对其中243例乳腺癌进行临床随访. 结果 500例乳腺癌中TNBC占17.6%(88/500).组织学类型主要为浸润性导管癌(NOS)、化生性癌和髓样癌.组织分级Ⅲ级占72.7%(64/88),高于激素受体阳性组和Her-2高表达组(P=0.000).TNBC中CK5/6阳性率30.7%(27/88),EGFR阳性率34.1%(30/88).TNBC中ERCC1和KIT阳性率分别为28.4%(25/88)和34.1%(30/88),均分别高于激素受体阳性组和Her-2高表达组(P=0.032和P=0.026).TNBC 3年累积生存率为71.5%,低于激素受体阳性组(P=0.021),与Her-2高表达组差异无统计学意义(P=0.474). 结论 TNBC是一类具有高侵袭性病理特征和预后不良的乳腺癌;部分病例表达EGFR和ERCC1.     

雌、孕激素受体和Her-2阴性乳腺癌的临床病理特征

Objective To study the clinicopathologic characteristics of triple-negative breast cancer (TNBC) and its value in the prediction of prognosis. Method In this study,500 cases of female breast cancers were examined immunohistochcmically for the TNBC. The clinicopathologic characteristics of the 243 TNBC cases were inspected. Results TNBC accounted for 17.6% (88/500) of the 500 breast cancers. The histological types of the TNBC included mainly infihrative ductal carcinoma, metaplastic carcinoma and medullar carcinoma. Among those, histological grade Ⅲ accounted for 72.7% (64/88) of all the TNBC and was more common than that in hormone receptor positive breast cancers (HR+ group ) and Her-2 overexpression breast cancers (Her-2 group)(P=0.000). The positive rates of CK5/6 and EGFR in the TNBC were 30.7% (27/88) and 34.1% (30/88), respectively. The positive rates of ERCC1 and KIT in the TNBC were 28.4% (25/88) and 34.1% (30/88), respectively, Both of which were higher than those in the HR + group and Her-2 group, respectively (P=0.032 and P=0.026). 3-year survival rate of the TNBC was 71.5% and it was lower than that of HR group (P=0.021) and not significantly different from that of Her-2 group (P=0.474). Conclusions TNBC is the breast cancer with high aggressive pathologic futures and poor prognosis. EGFR and ERCC1 expression were positive in a portion of TNBC cases.     

原发性乳腺恶性淋巴瘤6例

原发性乳腺恶性淋巴瘤（primary breast lymphoma，PBL），临床上极少见。我院白1994年1月-2006年3月共收治6例乳腺恶性淋巴瘤，均经手术病理证实，参考有关文献对该疾病予以复习，现报告如下。     

雌、孕激素受体和Her-2阴性乳腺癌的临床病理特征

Objective To study the clinicopathologic characteristics of triple-negative breast cancer (TNBC) and its value in the prediction of prognosis. Method In this study,500 cases of female breast cancers were examined immunohistochcmically for the TNBC. The clinicopathologic characteristics of the 243 TNBC cases were inspected. Results TNBC accounted for 17.6% (88/500) of the 500 breast cancers. The histological types of the TNBC included mainly infihrative ductal carcinoma, metaplastic carcinoma and medullar carcinoma. Among those, histological grade Ⅲ accounted for 72.7% (64/88) of all the TNBC and was more common than that in hormone receptor positive breast cancers (HR+ group ) and Her-2 overexpression breast cancers (Her-2 group)(P=0.000). The positive rates of CK5/6 and EGFR in the TNBC were 30.7% (27/88) and 34.1% (30/88), respectively. The positive rates of ERCC1 and KIT in the TNBC were 28.4% (25/88) and 34.1% (30/88), respectively, Both of which were higher than those in the HR + group and Her-2 group, respectively (P=0.032 and P=0.026). 3-year survival rate of the TNBC was 71.5% and it was lower than that of HR group (P=0.021) and not significantly different from that of Her-2 group (P=0.474). Conclusions TNBC is the breast cancer with high aggressive pathologic futures and poor prognosis. EGFR and ERCC1 expression were positive in a portion of TNBC cases.